Ab­b­Vie inks deal with Parvus; Sofinno­va in­vests in Cure51

Plus, news about Aque­s­tive Ther­a­peu­tics and Cy­bin:

Ab­b­Vie en­lists Parvus Ther­a­peu­tics for IBD pact: Ab­b­Vie will have the op­tion to de­vel­op and com­mer­cial­ize Parvus’ ther­a­pies for in­flam­ma­to­ry bow­el dis­eases (IBD). Parvus’ ther­a­pies trig­ger T cells to grow and turn in­to reg­u­la­to­ry T cells — a spe­cial­ized type of T cell that can sup­press the im­mune sys­tem.

The deal adds an­oth­er pipeline op­tion to Ab­b­Vie’s IBD fran­chise, which in­cludes Rin­voq and Skyrizi. And it adds to Parvus’ list of phar­ma col­lab­o­ra­tors, which in­clude No­var­tis and Roche’s Genen­tech. Fi­nan­cial de­tails of the li­cens­ing deal were not dis­closed, though Parvus could re­ceive a po­ten­tial eq­ui­ty in­vest­ment from Ab­b­Vie. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER